{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T05:01:12Z","timestamp":1666674072540},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1055\/a-1825-4967","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T22:30:18Z","timestamp":1666650618000},"page":"1383-1390","source":"Crossref","is-referenced-by-count":0,"title":["Einsatz antifibrotischer Medikamente bei interstitiellen Lungenerkrankungen"],"prefix":"10.1055","volume":"147","author":[{"given":"Claus-Peter","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Kneidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"L Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00564-2018","article-title":"Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis","volume":"52","author":"G Kwapiszewska","year":"2018","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"G Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12890-018-0599-3","article-title":"N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia","volume":"18","author":"J M Oldham","year":"2018","journal-title":"BMC Pulm Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"P W Noble","year":"2011","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"T E King","year":"2014","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"L Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1055\/s-0043-106160","article-title":"S2k-Leitlinie Idiopathische Lungenfibrose \u2013 Update zur medikament\u00f6sen Therapie 2017","volume":"71","author":"J Behr","year":"2017","journal-title":"Pneumologie"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/13993003.01966-2015","article-title":"Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function","volume":"48","author":"C Albera","year":"2016","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01339-2016","article-title":"Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis","volume":"49","author":"H R Collard","year":"2017","journal-title":"Eur Respir J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000479976","article-title":"An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)","volume":"94","author":"U Costabel","year":"2017","journal-title":"Respiration"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e000105","DOI":"10.1136\/bmjresp-2015-000105","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"L Lancaster","year":"2016","journal-title":"BMJ Open Respir Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"B Crestani","year":"2019","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thoraxjnl-2016-209701","article-title":"Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension","volume":"73","author":"L Richeldi","year":"2018","journal-title":"Thorax"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12931-022-01976-0","article-title":"Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis","volume":"23","author":"M Kreuter","year":"2022","journal-title":"Respir Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1513\/AnnalsATS.202007-901OC","article-title":"Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis","volume":"18","author":"T M Dempsey","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial","volume":"197","author":"C Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"V Cottin","year":"2019","journal-title":"Respir Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00393-019-00724-y","article-title":"Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung","volume":"79","author":"A Prasse","year":"2020","journal-title":"Z\u00a0Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"O Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"N Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"K R Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04587-2020","article-title":"Effects of nintedanib by inclusion criteria for progression of interstitial lung disease","volume":"59","author":"T M Maher","year":"2022","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases \u2013 subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"A U Wells","year":"2020","journal-title":"Lancet Resp Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"G Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"T M Maher","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"J Behr","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(21)00173-9","article-title":"Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed","volume":"9","author":"A U Wells","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"issue":"06","key":"ref29","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","article-title":"Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis","volume":"19","author":"M Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000495046","article-title":"Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potenzial Adverse Events","volume":"97","author":"E Bendstrup","year":"2019","journal-title":"Respiration"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40268-017-0221-9","article-title":"Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update","volume":"18","author":"J A Rodr\u00edguez-Portal","year":"2018","journal-title":"Drugs R D"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1825-4967.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T22:31:11Z","timestamp":1666650671000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1825-4967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,10,24]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1825-4967","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}